0001179110-20-004114.txt : 20200325 0001179110-20-004114.hdr.sgml : 20200325 20200325162219 ACCESSION NUMBER: 0001179110-20-004114 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200323 FILED AS OF DATE: 20200325 DATE AS OF CHANGE: 20200325 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Albers Jeffrey W. CENTRAL INDEX KEY: 0001638474 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 20742402 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 45 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-03-23 0 0001597264 Blueprint Medicines Corp BPMC 0001638474 Albers Jeffrey W. C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2020-03-23 4 M 0 20000 1.87 A 141434 D Common Stock 2020-03-23 4 M 0 80 1.87 A 141514 D Common Stock 2020-03-23 4 M 0 19920 8.80 A 161434 D Common Stock 2020-03-23 4 S 0 484 55.34 D 160950 D Common Stock 2020-03-23 4 S 0 3293 54.62 D 157657 D Common Stock 2020-03-23 4 S 0 1936 53.54 D 155721 D Common Stock 2020-03-23 4 S 0 2100 52.11 D 153621 D Common Stock 2020-03-23 4 S 0 8850 51.30 D 144771 D Common Stock 2020-03-23 4 S 0 3337 50.40 D 141434 D Stock Option (Right to Buy) 1.87 2020-03-23 4 M 0 20000 0 D 2024-07-30 Common Stock 20000 173903 D Stock Option (Right to Buy) 1.87 2020-03-23 4 M 0 80 0 D 2024-07-30 Common Stock 80 0 D Stock Option (Right to Buy) 8.80 2020-03-23 4 M 0 19920 0 D 2025-02-10 Common Stock 19920 87170 D Effected pursuant to a trading plan adopted on December 11, 2018 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.25 to $55.43 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (7) to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.15 to $55.04 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.06 to $53.93 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.84 to $52.805 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.84 to $51.82 per share. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.74 per share. This option was granted on July 30, 2014 and is fully vested. This option was granted on February 10, 2015 and is fully vested. /s/ Christopher Frankenfield, Attorney-in-Fact 2020-03-25